{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:38:47Z","timestamp":1759333127813,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jcjo.2017.03.018","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T04:30:21Z","timestamp":1497414621000},"page":"e163-e167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mooren\u2019s ulcerative keratitis after systemic pegylated interferon alpha2a in chronic hepatitis C"],"prefix":"10.1016","volume":"52","author":[{"given":"Joon Hyung","family":"Yeo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2017.03.018_bib1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1634\/theoncologist.2011-0324","article-title":"Retinopathy associated with adjuvant high-dose interferon-alpha2b in a patient with resected melanoma: a case report and review of the literature","volume":"17","author":"Monzon","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.jcjo.2017.03.018_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.mcg.0000135897.30038.16","article-title":"Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection","volume":"38","author":"Willson","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib3","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMct061675","article-title":"Peginterferon and ribavirin for chronic hepatitis C","volume":"355","author":"Hoofnagle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2017.03.018_bib4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0161-6420(94)31291-7","article-title":"Mooren-type hepatitis C virus-associated corneal ulceration","volume":"101","author":"Wilson","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.03.018_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.eye.6700604","article-title":"Hepatitis C virus-associated keratitis","volume":"18","author":"Jain","year":"2004","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2017.03.018_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJM199307013290118","article-title":"Mooren\u2019s corneal ulcers and hepatitis C virus infection","volume":"329","author":"Wilson","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2017.03.018_bib7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ophtha.2006.09.024","article-title":"Treatment of Mooren\u2019s ulcer with topical administration of interferon alfa 2a","volume":"114","author":"Erdem","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.03.018_bib8","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.3748\/wjg.v12.i28.4602","article-title":"Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C","volume":"12","author":"Goncalves","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bjo.79.2.150","article-title":"Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa","volume":"79","author":"Hayasaka","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0168-8278(05)80331-9","article-title":"Optic tract neuropathy complicating low-dose interferon treatment","volume":"21","author":"Manesis","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/bjo.78.3.238-a","article-title":"Development of neovascular glaucoma in the course of interferon alfa therapy for hepatitis type C","volume":"78","author":"Ayaki","year":"1994","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib12","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bjo.85.10.1171","article-title":"Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin","volume":"85","author":"Jain","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bjo.82.3.323","article-title":"Interferon associated retinopathy","volume":"82","author":"Hayasaka","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1167\/iovs.06-0182","article-title":"Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C","volume":"48","author":"Nagaoka","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2017.03.018_bib15","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.3748\/wjg.v12.i23.3756","article-title":"Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C","volume":"12","author":"Okuse","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/01.ico.0000214216.75496.7e","article-title":"Mooren ulcer: an immunopathologic study","volume":"25","author":"Kafkala","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2017.03.018_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0002-9394(76)90058-1","article-title":"Autoimmune phenomenon in Mooren\u2019s ulcer","volume":"82","author":"Brown","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib18","first-page":"365","article-title":"Circulating antibodies to corneal tissue in a patient suffering from Mooren\u2019s ulcer (ulcus rodens corneae)","volume":"5","author":"Schaap","year":"1969","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0002-9394(71)90420-X","article-title":"Mooren\u2019s ulcer","volume":"71","author":"Wood","year":"1971","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.03.018_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.59566\/IJBS.2006.2299","article-title":"Sterile corneal ulcer and Sjogren\u2019s syndrome associated with long-term interferon alpha-2b treatment in a case of multiple myeloma","volume":"2","author":"Liu","year":"2006","journal-title":"Int J Biomed Sci"},{"key":"10.1016\/j.jcjo.2017.03.018_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418216308080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418216308080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:06:38Z","timestamp":1757793998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418216308080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0008418216308080"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2017.03.018","relation":{},"ISSN":["0008-4182"],"issn-type":[{"type":"print","value":"0008-4182"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mooren\u2019s ulcerative keratitis after systemic pegylated interferon alpha2a in chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2017.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}